vs
Idexx Laboratories(IDXX)とRithm Capital Corp.(RITM)の財務データ比較。上の社名をクリックして会社を切り替えられます
Idexx Laboratoriesの直近四半期売上が大きい($1.1B vs $828.2M、Rithm Capital Corp.の約1.3倍)。Idexx Laboratoriesの純利益率が高く(22.8% vs 13.2%、差は9.5%)。Idexx Laboratoriesの前年同期比売上増加率が高い(14.3% vs -40.0%)。過去8四半期でIdexx Laboratoriesの売上複合成長率が高い(6.4% vs -17.9%)
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
Rithm Capital Corp.はアメリカ合衆国ニューヨークに本社を置く投資運用会社で、不動産投資とオルタナティブ投資を主力事業としています。専門的な投資調査チームと豊富な市場経験を基に、投資家に長期的かつ安定したリターンの提供を目指しています。
IDXX vs RITM — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | ||
|---|---|---|
| 売上 | $1.1B | $828.2M |
| 純利益 | $248.2M | $109.5M |
| 粗利率 | 60.3% | — |
| 営業利益率 | 28.9% | — |
| 純利益率 | 22.8% | 13.2% |
| 売上前年比 | 14.3% | -40.0% |
| 純利益前年比 | 14.8% | 20.9% |
| EPS(希薄化後) | $3.09 | $0.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $828.2M | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $998.4M | $768.4M | ||
| Q4 24 | $954.3M | $2.1B | ||
| Q3 24 | $975.5M | $619.5M | ||
| Q2 24 | $1.0B | $1.2B |
| Q1 26 | — | $109.5M | ||
| Q4 25 | $248.2M | $85.0M | ||
| Q3 25 | $274.6M | $221.5M | ||
| Q2 25 | $294.0M | $311.7M | ||
| Q1 25 | $242.7M | $78.8M | ||
| Q4 24 | $216.1M | $290.2M | ||
| Q3 24 | $232.8M | $121.7M | ||
| Q2 24 | $203.3M | $235.6M |
| Q1 26 | — | — | ||
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | 13.8% | ||
| Q3 25 | 32.1% | 21.4% | ||
| Q2 25 | 33.6% | 25.2% | ||
| Q1 25 | 31.7% | 7.4% | ||
| Q4 24 | 27.4% | 23.8% | ||
| Q3 24 | 31.2% | 7.3% | ||
| Q2 24 | 26.3% | 23.6% |
| Q1 26 | — | 13.2% | ||
| Q4 25 | 22.8% | 5.7% | ||
| Q3 25 | 24.8% | 20.0% | ||
| Q2 25 | 26.5% | 25.6% | ||
| Q1 25 | 24.3% | 10.3% | ||
| Q4 24 | 22.7% | 14.0% | ||
| Q3 24 | 23.9% | 19.7% | ||
| Q2 24 | 20.3% | 19.2% |
| Q1 26 | — | $0.12 | ||
| Q4 25 | $3.09 | $0.09 | ||
| Q3 25 | $3.40 | $0.35 | ||
| Q2 25 | $3.63 | $0.53 | ||
| Q1 25 | $2.96 | $0.07 | ||
| Q4 24 | $2.62 | $0.50 | ||
| Q3 24 | $2.80 | $0.20 | ||
| Q2 24 | $2.44 | $0.43 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | — |
| 総負債低いほど良い | $450.0M | — |
| 株主資本純資産 | $1.6B | $9.1B |
| 総資産 | $3.4B | $53.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $180.1M | $1.8B | ||
| Q3 25 | $208.2M | $1.6B | ||
| Q2 25 | $164.6M | $1.6B | ||
| Q1 25 | $164.0M | $1.5B | ||
| Q4 24 | $288.3M | $1.5B | ||
| Q3 24 | $308.6M | $1.6B | ||
| Q2 24 | $401.6M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | $617.8M | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.6B | $8.4B | ||
| Q3 25 | $1.6B | $8.5B | ||
| Q2 25 | $1.5B | $7.9B | ||
| Q1 25 | $1.4B | $7.8B | ||
| Q4 24 | $1.6B | $7.8B | ||
| Q3 24 | $1.6B | $7.7B | ||
| Q2 24 | $1.6B | $7.3B |
| Q1 26 | — | $53.4B | ||
| Q4 25 | $3.4B | $53.1B | ||
| Q3 25 | $3.4B | $47.2B | ||
| Q2 25 | $3.3B | $44.3B | ||
| Q1 25 | $3.2B | $45.3B | ||
| Q4 24 | $3.3B | $46.0B | ||
| Q3 24 | $3.4B | $42.3B | ||
| Q2 24 | $3.4B | $42.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | 0.39× | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | — |
| FCFマージンFCF / 売上 | 29.9% | — |
| 設備投資強度設備投資 / 売上 | 2.7% | — |
| キャッシュ転換率営業CF / 純利益 | 1.43× | — |
| 直近12ヶ月FCF直近4四半期 | $1.1B | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $-114.6M | ||
| Q3 25 | $402.3M | $-2.0B | ||
| Q2 25 | $185.7M | $-557.1M | ||
| Q1 25 | $238.0M | $1.4B | ||
| Q4 24 | $262.0M | $-1.8B | ||
| Q3 24 | $220.1M | $768.1M | ||
| Q2 24 | $248.3M | $-55.7M |
| Q1 26 | — | — | ||
| Q4 25 | $326.3M | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $151.6M | — | ||
| Q1 25 | $207.9M | — | ||
| Q4 24 | $232.8M | — | ||
| Q3 24 | $192.0M | — | ||
| Q2 24 | $215.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 29.9% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 24.4% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 21.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | -1.35× | ||
| Q3 25 | 1.47× | -9.22× | ||
| Q2 25 | 0.63× | -1.79× | ||
| Q1 25 | 0.98× | 18.03× | ||
| Q4 24 | 1.21× | -6.04× | ||
| Q3 24 | 0.95× | 6.31× | ||
| Q2 24 | 1.22× | -0.24× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |